For Manuscript Submission, Check or Review Login please go to Submission Websites List.
For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.
Effects of the Oral Direct Thrombin Inhibitor Ximelagatran on P-Selectin Expression and Thrombin Generation in Atrial FibrillationWolzt M.a · Boström S.L.b · Svensson M.b · Wåhlander K.b,c · Grind M.d · Sarich T.C.e
aDepartment of Clinical Pharmacology, University of Vienna, Vienna, Austria; bAstraZeneca R&D, Mölndal, cDepartment of Clinical Chemistry and Transfusion Medicine, Sahlgrenska University Hospital, Göteborg, Sweden; dAstraZenca R&D Charnwood, Loughborough, UK; eAstraZeneca LP, Wilmington, Del., USA Corresponding Author
Troy C. Sarich, PhD
Experimental Medicine, AstraZeneca LP
PO Box 15347, C4C-123
Wilmington, DE 19850 (USA)
Tel. +1 302 885 8979, Fax +1 302 886 3386, E-Mail email@example.com
This study investigated the pharmacodynamic effects of the oral direct thrombin inhibitor ximelagatran on platelet activation and thrombin generation in patients with nonvalvular atrial fibrillation. Using an open, group-matched study design, the effects of ximelagatran (36 mg twice daily for 5 days) were studied in 12 patients with permanent nonvalvular atrial fibrillation and in 12 healthy controls. After ximelagatran for 5 days, elevated platelet P-selectin expression in atrial fibrillation patients was lowered to that during coumarin treatment or in controls but had no effect in control subjects. Using the endogenous thrombin potential as a marker, ximelagatran decreased and delayed thrombin generation in both groups. In conclusion, direct thrombin inhibition with ximelagatran reduced elevated platelet P-selectin expression and inhibited thrombin generation.
© 2003 S. Karger AG, Basel